Compounds > cetaben
Page last updated: 2024-12-06

cetaben

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID47263
CHEMBL ID31907
SCHEMBL ID2112078
MeSH IDM0069579

Synonyms (36)

Synonym
benzoic acid, 4-(hexadecylamino)-
cetabeno [inn-spanish]
cetaben [inn]
4-(n-hexadecylamino)benzoic acid
brn 2748166
cetaben ,
cetabenum [inn-latin]
4-(hexadecylamino)benzoic acid
p-(hexadecylamino)benzoate
CHEMBL31907
cetabenum
cetabeno
unii-dtl5w0113x
dtl5w0113x ,
55986-43-1
FT-0603002
QXWKHSSBFQDQPR-UHFFFAOYSA-N
4-(n-hexadecylamino)-benzoic acid
p-hexadecylaminobenzoic acid
4-(hexadecylamino)-benzoic acid
4(hexadecylamino)benzoic acid
4-n-hexadecylaminobenzoic acid
NCGC00261985-01
SCHEMBL2112078
HMS3650E11
DTXSID70204558
J-520012
SR-01000944982-1
sr-01000944982
AKOS032947282
HY-119964
CS-0078843
SR-01000944982-2
Q27276596
hexadecylamino-p-amino benzoic acid
MS-25733

Research Excerpts

Treatment

Cetaben treatment correlated with a fragmentation and/or condensation of Golgi cisternae and the appearance of large electron-lucent vesicles. HepG2 cells were treated with the drug.

ExcerptReferenceRelevance
"Cetaben treatment correlated with a fragmentation and/or condensation of Golgi cisternae and the appearance of large electron-lucent vesicles."( The hypolipidemic compound cetaben induces changes in Golgi morphology and vesicle movement.
Kovacs, WJ; Schrader, M; Stangl, H; Walter, I, 2004)		1.34
"Cetaben treatment of HepG2 cells caused disintegration of Golgi regions and augmented mitochondrial matrix."( Cetaben-induced changes on the morphology and peroxisomal enzymes in MH1C1 rat hepatoma cells and HepG2 human hepatoblastoma cells.
Kovacs, W; Stangl, H; Walter, I, 2001)		2.47

Dosage Studied

ExcerptRelevanceReference
" The data obtained in the dose-response study of cetaben revealed a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body wt administered over 10 days, but the maximal effect was observed at 250 mg/kg."( Cetaben and fibrates both influence the activities of peroxisomal enzymes in different ways.
Chandoga, J; Hampl, L; Hocman, G; Rojeková, I, 1994)		1.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID175081In vivo Triglyceride lowering activity at dose as 0.01 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben.
AID175057In vivo Sterol lowering activity at dose as 0.03 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben.
AID175058In vivo sterol lowering activity, dosed as 0.03 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben.
AID31507In vitro inhibitory activity against acyl coenzyme A:cholesterol acyltransferase (ACAT)1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben.
AID174922In vivo Sterol lowering activity at dose as 0.01% of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben.
AID31508In vitro inhibition of acyl coenzyme A:cholesterol acyltransferase1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben.
AID175250In vivo Triglyceride lowering activity at a dose of 0.10 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben.
AID175249In vivo triglyceride lowering activity dosed at 0.10 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben.
AID175061In vivo sterol lowering activity when dosed as 0.03 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben.
AID175071In vivo sterol lowering activity at dose of 0.10 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben.
AID175070In vivo sterol lowering activity dosed at 0.10 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben.
AID175238In vivo triglyceride lowering activity when dosed at 0.03 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben.
AID175045In vivo sterol lowering activity when dosed as 0.01 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben.
AID175102In vivo Triglyceride lowering activity at dose as 0.03 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben.
AID175253In vivo triglyceride lowering activity dosed at 0.10 % of the diet.1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben.
AID31509In vitro inhibitory activity against acyl coenzyme A:cholesterol acyltransferase1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben.
AID174921In vivo Sterol lowering activity at dose as 0.01 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben.
AID175082In vivo Triglyceride lowering activity at dose as 0.01 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben.
AID175101In vivo triglyceride lowering activity, dosed at 0.03 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben.
AID645239Antiviral activity against Rotavirus SA11 in MA104 cells assessed as inhibition of viral replication after 24 hrs by immunofluorescent assay and Western blotting analysis2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID175074In vivo sterol lowering activity at dose of 0.10 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben.
AID645241Cytotoxicity against monkey MA104 cells after 24 hrs2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID175085In vivo triglyceride lowering activity when dosed as 0.01 % of the diet1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (50.00)18.7374
1990's5 (27.78)18.2507
2000's3 (16.67)29.6817
2010's1 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.12 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index115.72 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (40.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-aminobenzoic acid
4-Aminobenzoic Acid: An aminobenzoic acid isomer that combines with pteridine and GLUTAMIC ACID to form FOLIC ACID. The fact that 4-aminobenzoic acid absorbs light throughout the UVB range has also resulted in its use as an ingredient in SUNSCREENS.. 4-ammoniobenzoate : A zwitterion obtained by transfer of a proton from the carboxy to the amino group of 4-aminobenzoic acid.. 4-aminobenzoic acid : An aminobenzoic acid in which the amino group is para to the carboxy group.		5.27170aminobenzoic acid;
aromatic amino-acid zwitterion		allergen;
Escherichia coli metabolite;
plant metabolite
aminopropionitrile
Aminopropionitrile: Reagent used as an intermediate in the manufacture of beta-alanine and pantothenic acid.		1.9710aminopropionitrileantineoplastic agent;
antirheumatic drug;
collagen cross-linking inhibitor;
plant metabolite
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		3.0510benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		3.0750aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clofibric acid
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.. clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.		2.3920aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		3.0510guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
4-aminobenzoic acid
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.. 4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.		5.27170aminobenzoate;
aromatic amino-acid anion		Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
troglitazone
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.		2.0710chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
digoxigenin
Digoxigenin: 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide. A cardenolide which is the aglycon of digoxin. Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh.. digoxigenin : A hydroxy steroid that consists of 5beta-cardanolide having a double bond at the 20(22)-position as well as hydroxy groups at the 3beta-, 12beta- and 14beta-positions. It has been isolated from the plant species of the genus Digitalis.		21012beta-hydroxy steroid;
14beta-hydroxy steroid;
3beta-hydroxy steroid;
3beta-sterol		hapten;
plant metabolite
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		3.4820delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
mevastatin
mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.		3.05102-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
betulinic acid
[no description available]		2.0710hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
pd 128042
PD 128042: structure given in first source		2.0710anilide
tert-butyloxycarbonyl-phenylalanyl-prolyl-arginal
tert-butyloxycarbonyl-phenylalanyl-prolyl-arginal: inhibits thrombin induced platelet aggregation; also a serine protease inhibitor		3.0510
vitamin d 2
Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.		1.9610hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide
cerulenin
Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.		2.0710epoxide;
monocarboxylic acid amide		antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor
triacsin c
triacsin C: from Streptomyces No. 1228; structure given in first source; an acyl-CoA synthetase antagonist. triacsin C : A nitroso compound that is N-undecylnitrous hydrazide carrying double bonds at positions 1,2,4, and 7. It is a long-chain fatty acyl CoA synthetase inhibitor and interferes with lipid metabolism by inhibiting the de novo synthesis of glycerolipids and cholesterol esters.		2.0710hydrazone;
nitroso compound;
olefinic compound		antimalarial;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.1.64 (retinoid isomerohydrolase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
vasodilator agent
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid: an anorectic fatty acid synthase inhibitor; structure in first source. (2R,3S)-C75 : A 4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid that has 2R,3S-configuration.		2.07104-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid;
gamma-lactone
a-922500
[no description available]		2.0710aromatic ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Hyperlipemia
[description not available]		02.3620
Arteriosclerosis
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.		04.3880
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		02.3620
Rotavirus Infections
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.		02.0710
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.6630
Enlarged Liver
[description not available]		03.2820
Leukocytopenia
[description not available]		01.9610
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		01.9610
Elevated Cholesterol
[description not available]		01.9610
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		01.9610
Coronary Heart Disease
[description not available]		02.8710
Hypolipoproteinemia
[description not available]		02.8710
Coronary Disease
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.		02.8710
Hepatocellular Carcinoma
[description not available]		02.6930
Cancer of Liver
[description not available]		01.9810
Experimental Hepatoma
[description not available]		01.9810
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.6930
Liver Neoplasms
Tumors or cancer of the LIVER.		01.9810
Hepatoblastoma
A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)		0710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9710